Sub: Appointment of Statutory Auditors of the Company
This is to inform you that the Members in their 18th Annual General Meeting held on Tuesday, the 20th September, 2022 have appointed M/s. J S Shah & Co., Chartered Accountants (Firm Registration No. 132059W) as Statutory Auditors of the Company for a period of 5 years from the conclusion of 18th Annual General Meeting till the conclusion of the 23rd Annual General Meeting to be held in the year 2027.
This is in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).
Kindly find the same in order and acknowledge receipt of the same.
Thanking you,
Yours faithfully,
for SAKAR HEALTHCARE LIMITED
Shah
Sanjaybhai
Digitally signed by Shah Sanjaybhai DN: c=IN, o=Personal, 2.5.4.20=90ff86251c69206eed5a2b79dca999fc4e295cfd998 30542076e8e55b22bc02a, postalCode=380007, st=Gujarat, serialNumber=0ef2733fceaf47bc4b5043367b2ccee0fd5e44 613fe40fe4e2c5506074a4aff6, cn=Shah Sanjaybhai
Date: 2022.09.20 15:21:46 +05'30'
SANJAY S. SHAH MANAGING DIRECTOR (DIN: 01515296)
Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 for Appointment of Statutory Auditor:
Sr. No.
Disclosure
Details
Requirement
(a)
Reason for change
The present Auditors of the Company, M/s. A.L. Thakkar & Co., Chartered
Accounts, Ahmedabad retired at the 18th Annual General Meeting upon
conclusion of their term.
Pursuant to Section 139(2) of the Companies Act, 2013, the Company can
appoint an Auditors firm for a term of five consecutive years. Accordingly,
the Board of Directors at its meeting held on 20th July, 2022 based on
recommendations of the Audit Committee, had approved the appointment of
M/s. J S Shah & Co., Chartered Accountants (Firm Registration No.
132059W) as the Statutory Auditors of the Company for a term of 5
consecutive years i.e. from the conclusion of the 18th AGM till the
conclusion of the 23rd AGM subject to the approval of shareholders.
(b)
Date & Terms of
M/s. J S Shah & Co. have been appointed as Statutory Auditors of the
Appointment
Company in 18th Annual General Meeting held on 20th September, 2022 for
a period of 5 years to hold office from the conclusion of the ensuing 18th
AGM till the conclusion of 23rd AGM.
(c)
Brief Profile
Experienced Chartered Accountant providing services of Taxation (Direct
and Indirect), Company Law, Auditing, Financial Management,
Management Consultancy, Accounting and Consultancy, Cost Auditing,
Loans, Insurance and Investments.
(d)
Disclosure of relationships
Unrelated to any Directors or KMP of the Company
with Director/ KMP
for SAKAR HEALTHCARE LIMITED
Shah
Sanjaybhai
Digitally signed by Shah Sanjaybhai DN: c=IN, o=Personal, 2.5.4.20=90ff86251c69206eed5a2b79dca999fc4e295cfd998 30542076e8e55b22bc02a, postalCode=380007, st=Gujarat, serialNumber=0ef2733fceaf47bc4b5043367b2ccee0fd5e44 613fe40fe4e2c5506074a4aff6, cn=Shah Sanjaybhai
Date: 2022.09.20 15:22:00 +05'30'
SANJAY S. SHAH MANAGING DIRECTOR (DIN: 01515296)
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sakar Healthcare Ltd. published this content on 20 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2022 10:29:09 UTC.
Sakar Healthcare Limited is an India-based pharmaceutical formulations company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablet, capsule, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages and research & development of above products. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. The Company's product portfolio includes approximately 175 formulations for the international markets, 292 registered brands under its own name in more than 24 therapeutic areas. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. The Company has set up a research-driven vertically integrated with API for oncology formulation manufacturing unit.